SCP Vitalife Partners β Full Portfolio
20 tracked investments Β· listed companies and verified rows first
BiotechMarlborough, US
Charles Remsberg(Executive Officer)Larry Jasinski(Executive Officer, Director)Michael Lawless(Executive Officer)Almog Adar(Executive Officer)Jeannine Lynch(Executive Officer)Hadar Levy(Director)
Board seatWayne B. WeismanJeff DykanΒ· per SEC Form D Β· $8.8M raise Β· filed Jul 2020
Glaukos develops surgical and pharmaceutical therapies for ophthalmic diseases including glaucoma, corneal health, and retinal disease.
BiotechHealthtechMedical DevicesWaltham, US
Jason Hong(Director)David F. Muller(Executive Officer, Director)Robert Palmisano(Director)Philip J. Ferneau(Director)M. Carl Johnson, III(Director)David Berry(Director)
Board seatJeff DykanΒ· per SEC Form D
Echo360 provides learning engagement and analytics software to educational institutions and organizations.
EdTechEnterprise SoftwareSaaSReston, US
Frederick G.I. Singer(Executive Officer, Director)Jon Patty(Director)Rohit K. Seth(Director)Janet Hill(Director)Evan Morgan(Director)Anthony Abate(Executive Officer)
Board seatWayne B. WeismanΒ· per SEC Form D Β· $7.5M raise Β· filed Jan 2016
Ivenix makes an intelligent infusion pump system for hospital settings that delivers intravenous medications to patients while incorporating safeguards to reduce medication errors.
BiotechHealthtechMedical DevicesAmesbury, US
John M. Douglass(Director)John Sokolowski(Executive Officer)John K. Clarke(Director)Jesse Ambrosina(Executive Officer)Colin J. Foster(Director)Darrell J. Crate(Director)
Board seatWayne B. WeismanΒ· per SEC Form D
Specialty biopharmaceutical company developing differentiated prescription drugs for analgesia, anesthesia, sedation, and chronic pain management.
BiotechMalvern, US
Gerri A. Henwood(Executive Officer)
Board seatAbraham LudomirskiWayne B. WeismanWinston J. ChurchillΒ· per SEC Form D
Developing innovative biodegradable hydrogels for local repair of damaged cartilage and bone with unique in-vivo biodegradation profiles.
BiotechHerzliya
Galit Reske(Executive Officer)Arie Gordashnikov(Executive Officer)Susan Alpert(Director)Pini Ben-Elazar(Director)Keith Valentine(Director)Efraim Cohen-Arazi(Director)
Board seatJeff DykanΒ· per SEC Form D
Applies electro-optic infrared technology for non-contact pharmacological tests including counterfeit drug identification and pharmaceutical quality assurance.
Endospan develops endovascular stent graft systems, including the NEXUS Multi-Branch Aortic Arch Stent Graft System, for repairing aortic aneurysms and dissections in patients whose anatomy is unsuitable for traditional EVAR/TEVAR therapy.
HealthtechMedical Devices
Kevin Mayberry(Chief Executive Officer)Gadi Divald(Chief Financial Officer)
Cell therapy company focused on dermal-based regenerative therapy with proprietary scalable cell-manufacturing technology.
Biopharmaceutical company developing novel therapeutics for neurological diseases, initially targeting Parkinson's disease with potential disease modification.
Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.
Media & Entertainment
Commercializing CE-marked and FDA-cleared surgical devices for gastro-intestinal surgery using Nitinol-based products for natural tissue closure.
Developed an innovative automated clinical in-vitro diagnostic system providing real-time pathogen detection and identification without reagents.
BiotechRehovot
Ellen Cunniff(Executive Officer)Jonathan Gurfinkel(Executive Officer, Director)Eduard J. Ludwig(Director)Meir Hadar(Director)Gal Ingber(Executive Officer)Zvika Blutstein(Executive Officer)
Regentis Biomaterials develops regenerative medicine products for tissue repair, focused on orthopedic cartilage and bone treatments through its Gelrin degradable hydrogel platform.
BiotechHealthtechMedical Devices
Developing a non-invasive device for monitoring congestive heart failure through continuous measurement of pulmonary congestion parameters.
Developing a technology platform for orthopedics featuring a minimally invasive, motion-preserving interspinous spacer to treat low back and leg pain.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.